Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,7917906,half-life,"The pharmacokinetics of HMA in mice was studied by using high-performance liquid chromatography: after intraperitoneal injection of 20 micrograms g-1, the plasma level of HMA peaked at 8 microM after about 15 min and decreased to 1 microM at 120 min; the half-life was 35 min.","Inhibition of the regulation of intracellular pH: potential of 5-(N,N-hexamethylene) amiloride in tumour-selective therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917906/),min,35,3609,DB01275,Hydralazine
,7917906,surviving fraction,"Nigericin and HMA, at doses of 1.25 micrograms g-1 and 10 micrograms g-1 respectively, failed to cause significant cell killing in the EMT-6 murine tumour, but the surviving fraction was reduced to approximately 0.004 when hydralazine was administered with nigericin and HMA.","Inhibition of the regulation of intracellular pH: potential of 5-(N,N-hexamethylene) amiloride in tumour-selective therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917906/),,0.004,3610,DB01275,Hydralazine
,2600796,availability,"After HP administration, HPH appeared rapidly in plasma, but the HPH availability from HP amounted to only 17.8 +/- 3.7%, based on the comparison between the area under the plasma concentration curves of formed and iv HPH.","Pharmacokinetics and biotransformation of hydralazine acetone hydrazone, a metabolite of hydralazine, in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600796/),%,17.8,23246,DB01275,Hydralazine
,2600796,fraction,"The fraction of HAH available to the systemic circulation as HPH was extremely low (7.8 +/- 2.2%), indicating that the conversion of HAH to HP was not so extensive.","Pharmacokinetics and biotransformation of hydralazine acetone hydrazone, a metabolite of hydralazine, in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600796/),%,7.8,23247,DB01275,Hydralazine
,7284051,area under the plasma concentration time curve (AUC),After an intravenous dose of 0.3 mg/kg the area under the plasma concentration time curve (AUC) varied over less than a twofold range 17.5-29.5 muM-minute.,Variability of plasma hydralazine concentrations in male hypertensive patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7284051/),muM-minute,17.5-29.5,23891,DB01275,Hydralazine
,7284051,AUC,"However, after a single oral dose, 1 mg/kg, and after at least the fifth dose of a regimen consisting of 1 mg/kg given every 12 hours, there were much wider variations in AUC values: 4.0-30.4 and 3.2-38.5 muM-minute, respectively.",Variability of plasma hydralazine concentrations in male hypertensive patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7284051/),muM-minute,4.0-30.4,23892,DB01275,Hydralazine
,7284051,AUC,"However, after a single oral dose, 1 mg/kg, and after at least the fifth dose of a regimen consisting of 1 mg/kg given every 12 hours, there were much wider variations in AUC values: 4.0-30.4 and 3.2-38.5 muM-minute, respectively.",Variability of plasma hydralazine concentrations in male hypertensive patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7284051/),muM-minute,3.2-38.5,23893,DB01275,Hydralazine
,7284051,"peak hydralazine concentration, Cp","Similar ranges in peak hydralazine concentration, Cp, were also noted, 0.12-1.31 muM after single oral dose and 0.10-1.39 muM after the multiple dose regimen.",Variability of plasma hydralazine concentrations in male hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7284051/),muM,0.12-1.31,23894,DB01275,Hydralazine
,7284051,"peak hydralazine concentration, Cp","Similar ranges in peak hydralazine concentration, Cp, were also noted, 0.12-1.31 muM after single oral dose and 0.10-1.39 muM after the multiple dose regimen.",Variability of plasma hydralazine concentrations in male hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7284051/),muM,0.10-1.39,23895,DB01275,Hydralazine
,22131238,time required,The time required for reduction in systolic and diastolic blood pressure was shorter for oral nifedipine group (24.0 ± 10.0 min) than intravenus Hydralazine group (34.8 ± 18.8 min) (P ≤ 0.016).,Comparison of the efficacy of nifedipine and hydralazine in hypertensive crisis in pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22131238/),min,24.0,25656,DB01275,Hydralazine
,22131238,time required,The time required for reduction in systolic and diastolic blood pressure was shorter for oral nifedipine group (24.0 ± 10.0 min) than intravenus Hydralazine group (34.8 ± 18.8 min) (P ≤ 0.016).,Comparison of the efficacy of nifedipine and hydralazine in hypertensive crisis in pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22131238/),min,34.8,25657,DB01275,Hydralazine
,22522748,K(I),"We report a method using cryopreserved human hepatocytes and the time-dependent AO inhibitor hydralazine (K(I) = 83 ± 27 μM, k(inact) = 0.063 ± 0.007 min(-1)), which estimates the contribution of AO metabolism relative to total hepatic clearance.",Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22522748/),μM,83,31438,DB01275,Hydralazine
,22522748,k(inact),"We report a method using cryopreserved human hepatocytes and the time-dependent AO inhibitor hydralazine (K(I) = 83 ± 27 μM, k(inact) = 0.063 ± 0.007 min(-1)), which estimates the contribution of AO metabolism relative to total hepatic clearance.",Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22522748/),1/[min],0.063,31439,DB01275,Hydralazine
,22522748,f(m(AO)),The f(m(AO)) values for the AO substrates ranged between 0.49 and 0.83.,Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22522748/),,0.49 and 0.83,31440,DB01275,Hydralazine
,2339102,AUCoral/dose,"Pharmacokinetic analysis showed that AUCoral/dose (5552 to 13218 mg-min/ml) and F (0.36 to 0.77) increased significantly with dose, indicating saturation of first-pass metabolism, as is seen in humans.",Hydralazine pharmacokinetics and interaction with food: an evaluation of the dog as an animal model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2339102/),[mg-min] / [ml],5552 to 13218,32462,DB01275,Hydralazine
,2339102,F,"Pharmacokinetic analysis showed that AUCoral/dose (5552 to 13218 mg-min/ml) and F (0.36 to 0.77) increased significantly with dose, indicating saturation of first-pass metabolism, as is seen in humans.",Hydralazine pharmacokinetics and interaction with food: an evaluation of the dog as an animal model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2339102/),,0.36 to 0.77,32463,DB01275,Hydralazine
,2339102,Total-body clearance,Total-body clearance (70 ml/min/kg) and steady-state volume of distribution (9 L/kg) were similar to human values.,Hydralazine pharmacokinetics and interaction with food: an evaluation of the dog as an animal model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2339102/),[ml] / [kg·min],70,32464,DB01275,Hydralazine
,2339102,steady-state volume of distribution,Total-body clearance (70 ml/min/kg) and steady-state volume of distribution (9 L/kg) were similar to human values.,Hydralazine pharmacokinetics and interaction with food: an evaluation of the dog as an animal model. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2339102/),[l] / [kg],9,32465,DB01275,Hydralazine
,3592861,peak concentrations (Cmax,"Concomitant administration of H caused a significant (p less than 0.05) increase in P peak concentrations (Cmax, 34 +/- 5: 73 +/- 10 ng/ml) and the area under plasma concentration time curve (AUC, 142 +/- 18: 254 +/- 56 ng/ml X hr) of P with significant (p less than 0.05) 24% reduction of the apparent oral clearance.",Influence of hydralazine on the pharmacokinetics of orally administered d-propranolol and lidocaine in conscious dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592861/),[ng] / [ml],34,32740,DB01275,Hydralazine
,3592861,peak concentrations (Cmax,"Concomitant administration of H caused a significant (p less than 0.05) increase in P peak concentrations (Cmax, 34 +/- 5: 73 +/- 10 ng/ml) and the area under plasma concentration time curve (AUC, 142 +/- 18: 254 +/- 56 ng/ml X hr) of P with significant (p less than 0.05) 24% reduction of the apparent oral clearance.",Influence of hydralazine on the pharmacokinetics of orally administered d-propranolol and lidocaine in conscious dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592861/),[ng] / [ml],73,32741,DB01275,Hydralazine
,3592861,area under plasma concentration time curve (AUC,"Concomitant administration of H caused a significant (p less than 0.05) increase in P peak concentrations (Cmax, 34 +/- 5: 73 +/- 10 ng/ml) and the area under plasma concentration time curve (AUC, 142 +/- 18: 254 +/- 56 ng/ml X hr) of P with significant (p less than 0.05) 24% reduction of the apparent oral clearance.",Influence of hydralazine on the pharmacokinetics of orally administered d-propranolol and lidocaine in conscious dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592861/),[ng] / [h·ml],142,32742,DB01275,Hydralazine
,3592861,area under plasma concentration time curve (AUC,"Concomitant administration of H caused a significant (p less than 0.05) increase in P peak concentrations (Cmax, 34 +/- 5: 73 +/- 10 ng/ml) and the area under plasma concentration time curve (AUC, 142 +/- 18: 254 +/- 56 ng/ml X hr) of P with significant (p less than 0.05) 24% reduction of the apparent oral clearance.",Influence of hydralazine on the pharmacokinetics of orally administered d-propranolol and lidocaine in conscious dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592861/),[ng] / [h·ml],254,32743,DB01275,Hydralazine
,2550637,AUC0-48 h,Co-administration of hydralazine significantly increased the area under the plasma concentration time curve (AUC) of lisinopril (AUC0-48 h 766.8 +/- 66.3 ng.h/ml (lisinopril) vs 1022.3 +/- 115.3 ng.h/ml (lisinopril + hydralazine)).,"Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550637/),[h·ng] / [ml],766.8,48253,DB01275,Hydralazine
,2550637,AUC0-48 h,Co-administration of hydralazine significantly increased the area under the plasma concentration time curve (AUC) of lisinopril (AUC0-48 h 766.8 +/- 66.3 ng.h/ml (lisinopril) vs 1022.3 +/- 115.3 ng.h/ml (lisinopril + hydralazine)).,"Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550637/),[h·ng] / [ml],1022.3,48254,DB01275,Hydralazine
,2550637,AUC,This did not occur with enalaprilat (AUC 710.1 +/- 51.2 ng.h/ml (enalapril) vs 681.9 +/- 44.9 ng.h/ml (enalapril + hydralazine); mean +/- SEM).,"Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550637/),[h·ng] / [ml],710.1,48255,DB01275,Hydralazine
,2550637,AUC,This did not occur with enalaprilat (AUC 710.1 +/- 51.2 ng.h/ml (enalapril) vs 681.9 +/- 44.9 ng.h/ml (enalapril + hydralazine); mean +/- SEM).,"Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550637/),[h·ng] / [ml],681.9,48256,DB01275,Hydralazine
,6716273,Cpmax,"Coadministration of oral hydralazine and propranolol in conscious dogs caused an increase in peak plasma concentration ( Cpmax ) and area under the oral plasma concentration-time curve (AUC) of propranolol ( Cpmax = 19.2 +/- 5.8 ng/ml, control; Cpmax = 91.5 +/- 12.8 ng/ml, posthydralazine : AUC = 65.7 +/- 14.6 ng X hr/ml, control; AUC = 152.4 +/- 23.9 ng X hr/ml, posthydralazine : mean +/- S.E.M., n = 5; P less than .01 and P less than .01), without change either in the peak plasma level, time to peak or plasma AUC of [14C] propranolol and metabolites (P greater than .70, P greater than .90 and P greater than .60, respectively) or in urinary recovery (urinary recovery = 39.7 +/- 4.3% dose, control; urinary recovery = 41.8 +/- 6.2% dose, posthydralazine ).","Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716273/),[ng] / [ml],19.2,51119,DB01275,Hydralazine
,6716273,Cpmax,"Coadministration of oral hydralazine and propranolol in conscious dogs caused an increase in peak plasma concentration ( Cpmax ) and area under the oral plasma concentration-time curve (AUC) of propranolol ( Cpmax = 19.2 +/- 5.8 ng/ml, control; Cpmax = 91.5 +/- 12.8 ng/ml, posthydralazine : AUC = 65.7 +/- 14.6 ng X hr/ml, control; AUC = 152.4 +/- 23.9 ng X hr/ml, posthydralazine : mean +/- S.E.M., n = 5; P less than .01 and P less than .01), without change either in the peak plasma level, time to peak or plasma AUC of [14C] propranolol and metabolites (P greater than .70, P greater than .90 and P greater than .60, respectively) or in urinary recovery (urinary recovery = 39.7 +/- 4.3% dose, control; urinary recovery = 41.8 +/- 6.2% dose, posthydralazine ).","Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716273/),[ng] / [ml],91.5,51120,DB01275,Hydralazine
,6716273,AUC,"Coadministration of oral hydralazine and propranolol in conscious dogs caused an increase in peak plasma concentration ( Cpmax ) and area under the oral plasma concentration-time curve (AUC) of propranolol ( Cpmax = 19.2 +/- 5.8 ng/ml, control; Cpmax = 91.5 +/- 12.8 ng/ml, posthydralazine : AUC = 65.7 +/- 14.6 ng X hr/ml, control; AUC = 152.4 +/- 23.9 ng X hr/ml, posthydralazine : mean +/- S.E.M., n = 5; P less than .01 and P less than .01), without change either in the peak plasma level, time to peak or plasma AUC of [14C] propranolol and metabolites (P greater than .70, P greater than .90 and P greater than .60, respectively) or in urinary recovery (urinary recovery = 39.7 +/- 4.3% dose, control; urinary recovery = 41.8 +/- 6.2% dose, posthydralazine ).","Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716273/),[h·ng] / [ml],65.7,51121,DB01275,Hydralazine
,6716273,AUC,"Coadministration of oral hydralazine and propranolol in conscious dogs caused an increase in peak plasma concentration ( Cpmax ) and area under the oral plasma concentration-time curve (AUC) of propranolol ( Cpmax = 19.2 +/- 5.8 ng/ml, control; Cpmax = 91.5 +/- 12.8 ng/ml, posthydralazine : AUC = 65.7 +/- 14.6 ng X hr/ml, control; AUC = 152.4 +/- 23.9 ng X hr/ml, posthydralazine : mean +/- S.E.M., n = 5; P less than .01 and P less than .01), without change either in the peak plasma level, time to peak or plasma AUC of [14C] propranolol and metabolites (P greater than .70, P greater than .90 and P greater than .60, respectively) or in urinary recovery (urinary recovery = 39.7 +/- 4.3% dose, control; urinary recovery = 41.8 +/- 6.2% dose, posthydralazine ).","Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716273/),[h·ng] / [ml],152.4,51122,DB01275,Hydralazine
,6716273,Oral bioavailability,"Oral bioavailability increased from 7.3 +/- 2.1 to 23.6 +/- 5.1% (mean +/- S.E.M., n = 5, P less than .025), hepatic extraction showed correspondingly inverse changes and estimated hepatic blood flow increased from 34.9 +/- 3.8 to 63.3 +/- 10.8 ml/min/kg (P less than .025).","Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716273/),%,7.3,51123,DB01275,Hydralazine
,6716273,Oral bioavailability,"Oral bioavailability increased from 7.3 +/- 2.1 to 23.6 +/- 5.1% (mean +/- S.E.M., n = 5, P less than .025), hepatic extraction showed correspondingly inverse changes and estimated hepatic blood flow increased from 34.9 +/- 3.8 to 63.3 +/- 10.8 ml/min/kg (P less than .025).","Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716273/),%,23.6,51124,DB01275,Hydralazine
,6716273,hepatic blood flow,"Oral bioavailability increased from 7.3 +/- 2.1 to 23.6 +/- 5.1% (mean +/- S.E.M., n = 5, P less than .025), hepatic extraction showed correspondingly inverse changes and estimated hepatic blood flow increased from 34.9 +/- 3.8 to 63.3 +/- 10.8 ml/min/kg (P less than .025).","Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow. ",QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716273/),[ml] / [kg·min],34.9,51125,DB01275,Hydralazine
,6716273,hepatic blood flow,"Oral bioavailability increased from 7.3 +/- 2.1 to 23.6 +/- 5.1% (mean +/- S.E.M., n = 5, P less than .025), hepatic extraction showed correspondingly inverse changes and estimated hepatic blood flow increased from 34.9 +/- 3.8 to 63.3 +/- 10.8 ml/min/kg (P less than .025).","Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow. ",QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716273/),[ml] / [kg·min],63.3,51126,DB01275,Hydralazine
,22031625,hepatic clearance (Cl(h)),"Estimated hepatic clearance (Cl(h)) for BIBX1382, carbazeran, O⁶-benzylguanine, zaleplon, and XK-469 using cryopreserved hepatocytes was 18, 17, 12, <4.3, and <4.3 ml · min⁻¹ · kg⁻¹, respectively.",Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22031625/),kg⁻¹·min⁻¹·ml,18,58219,DB01275,Hydralazine
,22031625,hepatic clearance (Cl(h)),"Estimated hepatic clearance (Cl(h)) for BIBX1382, carbazeran, O⁶-benzylguanine, zaleplon, and XK-469 using cryopreserved hepatocytes was 18, 17, 12, <4.3, and <4.3 ml · min⁻¹ · kg⁻¹, respectively.",Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22031625/),kg⁻¹·min⁻¹·ml,17,58220,DB01275,Hydralazine
,22031625,hepatic clearance (Cl(h)),"Estimated hepatic clearance (Cl(h)) for BIBX1382, carbazeran, O⁶-benzylguanine, zaleplon, and XK-469 using cryopreserved hepatocytes was 18, 17, 12, <4.3, and <4.3 ml · min⁻¹ · kg⁻¹, respectively.",Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22031625/),kg⁻¹·min⁻¹·ml,12,58221,DB01275,Hydralazine
<,22031625,hepatic clearance (Cl(h)),"Estimated hepatic clearance (Cl(h)) for BIBX1382, carbazeran, O⁶-benzylguanine, zaleplon, and XK-469 using cryopreserved hepatocytes was 18, 17, 12, <4.3, and <4.3 ml · min⁻¹ · kg⁻¹, respectively.",Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22031625/),kg⁻¹·min⁻¹·ml,4.3,58222,DB01275,Hydralazine
,22031625,hepatic clearance,"In addition, the estimated hepatic clearance value for O⁶-benzylguanine was within ∼80% of the observed total clearance in humans after intravenous administration (15 ml · min⁻¹ · kg⁻¹), indicating a reasonable level of quantitative activity from this in vitro system.",Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22031625/),kg⁻¹·min⁻¹·ml,15,58223,DB01275,Hydralazine
,22031625,total clearance,"In addition, the estimated hepatic clearance value for O⁶-benzylguanine was within ∼80% of the observed total clearance in humans after intravenous administration (15 ml · min⁻¹ · kg⁻¹), indicating a reasonable level of quantitative activity from this in vitro system.",Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22031625/),kg⁻¹·min⁻¹·ml,15,58224,DB01275,Hydralazine
,3508566,clearance,"The oral administration of hydralazine hydrochloride, 7.5 mg/kg, 15 min prior to antipyrine administration reduced antipyrine clearance from 9.66 +/- 1.18 to 8.19 +/- 0.76 ml/min/kg (P less than 0.05).",Effect of hydralazine on the elimination of antipyrine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3508566/),[ml] / [kg·min],9.66,61364,DB01275,Hydralazine
,3508566,clearance,"The oral administration of hydralazine hydrochloride, 7.5 mg/kg, 15 min prior to antipyrine administration reduced antipyrine clearance from 9.66 +/- 1.18 to 8.19 +/- 0.76 ml/min/kg (P less than 0.05).",Effect of hydralazine on the elimination of antipyrine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3508566/),[ml] / [kg·min],8.19,61365,DB01275,Hydralazine
,7056277,Peak plasma levels,"Peak plasma levels occurred after 2-3h and averaged 15, 27 and 45 microgram/l in the three dose groups.",Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056277/),[μg] / [l],15,65023,DB01275,Hydralazine
,7056277,Peak plasma levels,"Peak plasma levels occurred after 2-3h and averaged 15, 27 and 45 microgram/l in the three dose groups.",Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056277/),[μg] / [l],27,65024,DB01275,Hydralazine
,7056277,Peak plasma levels,"Peak plasma levels occurred after 2-3h and averaged 15, 27 and 45 microgram/l in the three dose groups.",Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056277/),[μg] / [l],45,65025,DB01275,Hydralazine
,7056277,Areas under the plasma concentration - time curves (AUC0 leads to 12),"Areas under the plasma concentration - time curves (AUC0 leads to 12), which were 75, 147 and 250 microgram 1(-1)h respectively, and cumulative urinary recovery (20%) were independent of the dose administered and the type of formulation.",Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056277/),μg,75,65026,DB01275,Hydralazine
,7056277,Areas under the plasma concentration - time curves (AUC0 leads to 12),"Areas under the plasma concentration - time curves (AUC0 leads to 12), which were 75, 147 and 250 microgram 1(-1)h respectively, and cumulative urinary recovery (20%) were independent of the dose administered and the type of formulation.",Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056277/),μg,147,65027,DB01275,Hydralazine
,7056277,Areas under the plasma concentration - time curves (AUC0 leads to 12),"Areas under the plasma concentration - time curves (AUC0 leads to 12), which were 75, 147 and 250 microgram 1(-1)h respectively, and cumulative urinary recovery (20%) were independent of the dose administered and the type of formulation.",Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056277/),μg,250,65028,DB01275,Hydralazine
,7056277,cumulative urinary recovery,"Areas under the plasma concentration - time curves (AUC0 leads to 12), which were 75, 147 and 250 microgram 1(-1)h respectively, and cumulative urinary recovery (20%) were independent of the dose administered and the type of formulation.",Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056277/),%,20,65029,DB01275,Hydralazine
,7056277,plasma clearance,"The plasma clearance was calculated to be 505 ml/min, renal clearance 108 ml/min and nonrenal clearance 396 ml/min.",Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056277/),[ml] / [min],505,65030,DB01275,Hydralazine
,7056277,renal clearance,"The plasma clearance was calculated to be 505 ml/min, renal clearance 108 ml/min and nonrenal clearance 396 ml/min.",Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056277/),[ml] / [min],108,65031,DB01275,Hydralazine
,7056277,nonrenal clearance,"The plasma clearance was calculated to be 505 ml/min, renal clearance 108 ml/min and nonrenal clearance 396 ml/min.",Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056277/),[ml] / [min],396,65032,DB01275,Hydralazine
,12271964,minimum detectable concentration,The minimum detectable concentration of INH was determined to be 0.5 mcg/ml.,[Bioavailability of isoniazid in healthy volunteers--fast and slow INH acetylators]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12271964/),[mcg] / [ml],0.5,68163,DB01275,Hydralazine
,21781652,C(max),"The C(max) and t(max) of hydralazine for fast acetylators were 208.4 ± 56.9 SD ng/ml and 2.8 ± 2.5 h, respectively.","Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21781652/),[ng] / [ml],208.4,68928,DB01275,Hydralazine
,21781652,t(max),"The C(max) and t(max) of hydralazine for fast acetylators were 208.4 ± 56.9 SD ng/ml and 2.8 ± 2.5 h, respectively.","Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21781652/),h,2.8,68929,DB01275,Hydralazine
,21781652,concentrations,"Among 85 cancer patients that received either 182 mg or 83 mg of hydralazine daily, according to their acetylator status, the mean concentrations of hydralazine in plasma were 239.1 ng/ml and 259.2 ng/ml for fast and slow acetylators, respectively.","Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21781652/),[ng] / [ml],239.1,68930,DB01275,Hydralazine
,21781652,concentrations,"Among 85 cancer patients that received either 182 mg or 83 mg of hydralazine daily, according to their acetylator status, the mean concentrations of hydralazine in plasma were 239.1 ng/ml and 259.2 ng/ml for fast and slow acetylators, respectively.","Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21781652/),[ng] / [ml],259.2,68931,DB01275,Hydralazine
,30464406,oral bioavailability,It suffers poor oral bioavailability (26%-50%) due to first-pass metabolism.,Hydralazine HCl rapidly disintegrating sublingual tablets: simple dosage form of higher bioavailability and enhanced clinical efficacy for potential rapid control on hypertensive preeclampsia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30464406/),%,26%-50,69706,DB01275,Hydralazine
,30464406,C max,"The drug bioavailability was significantly increased with C max = 28.2767±4.61 µg/mL, AUC(0-α) = 52.85±3.18 µg.h/mL, and T max = 0.33±0.011 hour in comparison to 18.0633±23.2 µg/mL, 33.18±5.18 µg⋅h/mL, and 0.75±0.025 hour for conventional oral tablets.",Hydralazine HCl rapidly disintegrating sublingual tablets: simple dosage form of higher bioavailability and enhanced clinical efficacy for potential rapid control on hypertensive preeclampsia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30464406/),[μg] / [ml],28.2767,69707,DB01275,Hydralazine
,30464406,AUC(0-α),"The drug bioavailability was significantly increased with C max = 28.2767±4.61 µg/mL, AUC(0-α) = 52.85±3.18 µg.h/mL, and T max = 0.33±0.011 hour in comparison to 18.0633±23.2 µg/mL, 33.18±5.18 µg⋅h/mL, and 0.75±0.025 hour for conventional oral tablets.",Hydralazine HCl rapidly disintegrating sublingual tablets: simple dosage form of higher bioavailability and enhanced clinical efficacy for potential rapid control on hypertensive preeclampsia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30464406/),[h·μg] / [ml],52.85,69708,DB01275,Hydralazine
,30464406,T max,"The drug bioavailability was significantly increased with C max = 28.2767±4.61 µg/mL, AUC(0-α) = 52.85±3.18 µg.h/mL, and T max = 0.33±0.011 hour in comparison to 18.0633±23.2 µg/mL, 33.18±5.18 µg⋅h/mL, and 0.75±0.025 hour for conventional oral tablets.",Hydralazine HCl rapidly disintegrating sublingual tablets: simple dosage form of higher bioavailability and enhanced clinical efficacy for potential rapid control on hypertensive preeclampsia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30464406/),h,0.33,69709,DB01275,Hydralazine
,30464406,T max,"The drug bioavailability was significantly increased with C max = 28.2767±4.61 µg/mL, AUC(0-α) = 52.85±3.18 µg.h/mL, and T max = 0.33±0.011 hour in comparison to 18.0633±23.2 µg/mL, 33.18±5.18 µg⋅h/mL, and 0.75±0.025 hour for conventional oral tablets.",Hydralazine HCl rapidly disintegrating sublingual tablets: simple dosage form of higher bioavailability and enhanced clinical efficacy for potential rapid control on hypertensive preeclampsia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30464406/),h,0.75,69710,DB01275,Hydralazine
,6705442,peak concentrations,"Hydralazine increased propranolol peak concentrations from 25 +/- 7 ng/ml to 61 +/- 10 and 85 +/- 11 ng/ml, reduced time to peak concentrations from 2.2 +/- 0.2 hr to 0.7 +/- 0.1 and 0.8 +/- 0.1 hr, and increased area under the propranolol concentration: time curves from 153 +/- 38 ng X ml-1 X hr to 246 +/- 64 and 324 ng X ml-1 X hr (in all cases P less than 0.05).",Mechanism by which hydralazine increases propranolol bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705442/),[ng] / [ml],25,80541,DB01275,Hydralazine
,6705442,peak concentrations,"Hydralazine increased propranolol peak concentrations from 25 +/- 7 ng/ml to 61 +/- 10 and 85 +/- 11 ng/ml, reduced time to peak concentrations from 2.2 +/- 0.2 hr to 0.7 +/- 0.1 and 0.8 +/- 0.1 hr, and increased area under the propranolol concentration: time curves from 153 +/- 38 ng X ml-1 X hr to 246 +/- 64 and 324 ng X ml-1 X hr (in all cases P less than 0.05).",Mechanism by which hydralazine increases propranolol bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705442/),[ng] / [ml],61,80542,DB01275,Hydralazine
,6705442,peak concentrations,"Hydralazine increased propranolol peak concentrations from 25 +/- 7 ng/ml to 61 +/- 10 and 85 +/- 11 ng/ml, reduced time to peak concentrations from 2.2 +/- 0.2 hr to 0.7 +/- 0.1 and 0.8 +/- 0.1 hr, and increased area under the propranolol concentration: time curves from 153 +/- 38 ng X ml-1 X hr to 246 +/- 64 and 324 ng X ml-1 X hr (in all cases P less than 0.05).",Mechanism by which hydralazine increases propranolol bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705442/),[ng] / [ml],85,80543,DB01275,Hydralazine
,6705442,time to peak concentrations,"Hydralazine increased propranolol peak concentrations from 25 +/- 7 ng/ml to 61 +/- 10 and 85 +/- 11 ng/ml, reduced time to peak concentrations from 2.2 +/- 0.2 hr to 0.7 +/- 0.1 and 0.8 +/- 0.1 hr, and increased area under the propranolol concentration: time curves from 153 +/- 38 ng X ml-1 X hr to 246 +/- 64 and 324 ng X ml-1 X hr (in all cases P less than 0.05).",Mechanism by which hydralazine increases propranolol bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705442/),h,2.2,80544,DB01275,Hydralazine
,6705442,time to peak concentrations,"Hydralazine increased propranolol peak concentrations from 25 +/- 7 ng/ml to 61 +/- 10 and 85 +/- 11 ng/ml, reduced time to peak concentrations from 2.2 +/- 0.2 hr to 0.7 +/- 0.1 and 0.8 +/- 0.1 hr, and increased area under the propranolol concentration: time curves from 153 +/- 38 ng X ml-1 X hr to 246 +/- 64 and 324 ng X ml-1 X hr (in all cases P less than 0.05).",Mechanism by which hydralazine increases propranolol bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705442/),h,0.7,80545,DB01275,Hydralazine
,6705442,time to peak concentrations,"Hydralazine increased propranolol peak concentrations from 25 +/- 7 ng/ml to 61 +/- 10 and 85 +/- 11 ng/ml, reduced time to peak concentrations from 2.2 +/- 0.2 hr to 0.7 +/- 0.1 and 0.8 +/- 0.1 hr, and increased area under the propranolol concentration: time curves from 153 +/- 38 ng X ml-1 X hr to 246 +/- 64 and 324 ng X ml-1 X hr (in all cases P less than 0.05).",Mechanism by which hydralazine increases propranolol bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705442/),h,0.8,80546,DB01275,Hydralazine
,6705442,area under the propranolol concentration: time curves,"Hydralazine increased propranolol peak concentrations from 25 +/- 7 ng/ml to 61 +/- 10 and 85 +/- 11 ng/ml, reduced time to peak concentrations from 2.2 +/- 0.2 hr to 0.7 +/- 0.1 and 0.8 +/- 0.1 hr, and increased area under the propranolol concentration: time curves from 153 +/- 38 ng X ml-1 X hr to 246 +/- 64 and 324 ng X ml-1 X hr (in all cases P less than 0.05).",Mechanism by which hydralazine increases propranolol bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705442/),[h·ng] / [ml],153,80547,DB01275,Hydralazine
,6705442,area under the propranolol concentration: time curves,"Hydralazine increased propranolol peak concentrations from 25 +/- 7 ng/ml to 61 +/- 10 and 85 +/- 11 ng/ml, reduced time to peak concentrations from 2.2 +/- 0.2 hr to 0.7 +/- 0.1 and 0.8 +/- 0.1 hr, and increased area under the propranolol concentration: time curves from 153 +/- 38 ng X ml-1 X hr to 246 +/- 64 and 324 ng X ml-1 X hr (in all cases P less than 0.05).",Mechanism by which hydralazine increases propranolol bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705442/),[h·ng] / [ml],246,80548,DB01275,Hydralazine
,6705442,area under the propranolol concentration: time curves,"Hydralazine increased propranolol peak concentrations from 25 +/- 7 ng/ml to 61 +/- 10 and 85 +/- 11 ng/ml, reduced time to peak concentrations from 2.2 +/- 0.2 hr to 0.7 +/- 0.1 and 0.8 +/- 0.1 hr, and increased area under the propranolol concentration: time curves from 153 +/- 38 ng X ml-1 X hr to 246 +/- 64 and 324 ng X ml-1 X hr (in all cases P less than 0.05).",Mechanism by which hydralazine increases propranolol bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705442/),[h·ng] / [ml],324,80549,DB01275,Hydralazine
,17854237,maximum observed concentrations (C(max)),"In phase B, the maximum observed concentrations (C(max)) were 65.9 +/- 53.9, 28.2 +/- 15.8 and 51.5 +/- 54.3 ng/mL of unchanged hydralazine, and 23.1 +/- 12.3, 21.7 +/- 13.4 and 26.7 +/- 18.7 ng/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[ng] / [ml],65.9,97282,DB01275,Hydralazine
,17854237,maximum observed concentrations (C(max)),"In phase B, the maximum observed concentrations (C(max)) were 65.9 +/- 53.9, 28.2 +/- 15.8 and 51.5 +/- 54.3 ng/mL of unchanged hydralazine, and 23.1 +/- 12.3, 21.7 +/- 13.4 and 26.7 +/- 18.7 ng/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[ng] / [ml],28.2,97283,DB01275,Hydralazine
,17854237,maximum observed concentrations (C(max)),"In phase B, the maximum observed concentrations (C(max)) were 65.9 +/- 53.9, 28.2 +/- 15.8 and 51.5 +/- 54.3 ng/mL of unchanged hydralazine, and 23.1 +/- 12.3, 21.7 +/- 13.4 and 26.7 +/- 18.7 ng/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[ng] / [ml],51.5,97284,DB01275,Hydralazine
,17854237,maximum observed concentrations (C(max)),"In phase B, the maximum observed concentrations (C(max)) were 65.9 +/- 53.9, 28.2 +/- 15.8 and 51.5 +/- 54.3 ng/mL of unchanged hydralazine, and 23.1 +/- 12.3, 21.7 +/- 13.4 and 26.7 +/- 18.7 ng/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[ng] / [ml],23.1,97285,DB01275,Hydralazine
,17854237,maximum observed concentrations (C(max)),"In phase B, the maximum observed concentrations (C(max)) were 65.9 +/- 53.9, 28.2 +/- 15.8 and 51.5 +/- 54.3 ng/mL of unchanged hydralazine, and 23.1 +/- 12.3, 21.7 +/- 13.4 and 26.7 +/- 18.7 ng/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[ng] / [ml],21.7,97286,DB01275,Hydralazine
,17854237,maximum observed concentrations (C(max)),"In phase B, the maximum observed concentrations (C(max)) were 65.9 +/- 53.9, 28.2 +/- 15.8 and 51.5 +/- 54.3 ng/mL of unchanged hydralazine, and 23.1 +/- 12.3, 21.7 +/- 13.4 and 26.7 +/- 18.7 ng/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[ng] / [ml],26.7,97287,DB01275,Hydralazine
,17854237,area under the blood/plasma concentration-time curve (AUC),"The area under the blood/plasma concentration-time curve (AUC) values were 32.6 +/- 13.4, 23.3 +/- 15.1 and 32.6 +/- 18.5 ng x h/mL of hydralazine, and 24.4 +/- 9.0, 24.8 +/- 8.0 and 23.5 +/- 6.3 ng x h/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[h·ng] / [ml],32.6,97288,DB01275,Hydralazine
,17854237,area under the blood/plasma concentration-time curve (AUC),"The area under the blood/plasma concentration-time curve (AUC) values were 32.6 +/- 13.4, 23.3 +/- 15.1 and 32.6 +/- 18.5 ng x h/mL of hydralazine, and 24.4 +/- 9.0, 24.8 +/- 8.0 and 23.5 +/- 6.3 ng x h/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[h·ng] / [ml],23.3,97289,DB01275,Hydralazine
,17854237,area under the blood/plasma concentration-time curve (AUC),"The area under the blood/plasma concentration-time curve (AUC) values were 32.6 +/- 13.4, 23.3 +/- 15.1 and 32.6 +/- 18.5 ng x h/mL of hydralazine, and 24.4 +/- 9.0, 24.8 +/- 8.0 and 23.5 +/- 6.3 ng x h/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[h·ng] / [ml],32.6,97290,DB01275,Hydralazine
,17854237,area under the blood/plasma concentration-time curve (AUC),"The area under the blood/plasma concentration-time curve (AUC) values were 32.6 +/- 13.4, 23.3 +/- 15.1 and 32.6 +/- 18.5 ng x h/mL of hydralazine, and 24.4 +/- 9.0, 24.8 +/- 8.0 and 23.5 +/- 6.3 ng x h/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[h·ng] / [ml],24.4,97291,DB01275,Hydralazine
,17854237,area under the blood/plasma concentration-time curve (AUC),"The area under the blood/plasma concentration-time curve (AUC) values were 32.6 +/- 13.4, 23.3 +/- 15.1 and 32.6 +/- 18.5 ng x h/mL of hydralazine, and 24.4 +/- 9.0, 24.8 +/- 8.0 and 23.5 +/- 6.3 ng x h/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[h·ng] / [ml],24.8,97292,DB01275,Hydralazine
,17854237,area under the blood/plasma concentration-time curve (AUC),"The area under the blood/plasma concentration-time curve (AUC) values were 32.6 +/- 13.4, 23.3 +/- 15.1 and 32.6 +/- 18.5 ng x h/mL of hydralazine, and 24.4 +/- 9.0, 24.8 +/- 8.0 and 23.5 +/- 6.3 ng x h/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[h·ng] / [ml],23.5,97293,DB01275,Hydralazine
,3919988,ClB,"Forty minutes after the start of nitroglycerin therapy, ICG ClB fell from a baseline of 648 +/- 98 to 607 +/- 151 ml/min, and was further decreased to 578 +/- 98 ml/min 80 minutes after dosing.","Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919988/),[ml] / [min],648,100257,DB01275,Hydralazine
,3919988,ClB,"Forty minutes after the start of nitroglycerin therapy, ICG ClB fell from a baseline of 648 +/- 98 to 607 +/- 151 ml/min, and was further decreased to 578 +/- 98 ml/min 80 minutes after dosing.","Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919988/),[ml] / [min],607,100258,DB01275,Hydralazine
,3919988,ClB,"Forty minutes after the start of nitroglycerin therapy, ICG ClB fell from a baseline of 648 +/- 98 to 607 +/- 151 ml/min, and was further decreased to 578 +/- 98 ml/min 80 minutes after dosing.","Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919988/),[ml] / [min],578,100259,DB01275,Hydralazine
,3919988,ClB,"ICG ClB was 744 +/- 376, 721 +/- 218, and 763 +/- 195 ml/min at baseline, 40 minutes, and 80 minutes after dosing.","Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919988/),[ml] / [min],744,100260,DB01275,Hydralazine
,3919988,ClB,"ICG ClB was 744 +/- 376, 721 +/- 218, and 763 +/- 195 ml/min at baseline, 40 minutes, and 80 minutes after dosing.","Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919988/),[ml] / [min],721,100261,DB01275,Hydralazine
,3919988,ClB,"ICG ClB was 744 +/- 376, 721 +/- 218, and 763 +/- 195 ml/min at baseline, 40 minutes, and 80 minutes after dosing.","Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919988/),[ml] / [min],763,100262,DB01275,Hydralazine
,3919988,ClB,"After this meal, ICG ClB increased from 656 +/- 107 to 811 +/- 141 and 801 +/- 132 ml/min at 40 and 80 minutes after dosing.","Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919988/),[ml] / [min],656,100263,DB01275,Hydralazine
,3919988,ClB,"After this meal, ICG ClB increased from 656 +/- 107 to 811 +/- 141 and 801 +/- 132 ml/min at 40 and 80 minutes after dosing.","Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919988/),[ml] / [min],811,100264,DB01275,Hydralazine
,3919988,ClB,"After this meal, ICG ClB increased from 656 +/- 107 to 811 +/- 141 and 801 +/- 132 ml/min at 40 and 80 minutes after dosing.","Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919988/),[ml] / [min],801,100265,DB01275,Hydralazine
,31257615,apparent oral clearance,"During pregnancy, when compared with the SA group, the RA group had faster weight-adjusted hydralazine apparent oral clearance (70.0 ± 13.6 vs 20.1 ± 6.9 L/h, P < .05), lower dose-normalized area under the concentration-time curve (AUC; 1.5 ± 0.8 vs 5.9 ± 3.7 ng·h/mL, P < .05), lower dose-normalized peak concentrations (0.77 ± 0.51 vs 4.04 ± 3.18 ng/mL, P < .05), and larger weight-adjusted apparent oral volume of distribution (302 ± 112 vs 116 ± 45 L/kg, P < .05).",Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257615/),[l] / [h],70.0,104529,DB01275,Hydralazine
,31257615,apparent oral clearance,"During pregnancy, when compared with the SA group, the RA group had faster weight-adjusted hydralazine apparent oral clearance (70.0 ± 13.6 vs 20.1 ± 6.9 L/h, P < .05), lower dose-normalized area under the concentration-time curve (AUC; 1.5 ± 0.8 vs 5.9 ± 3.7 ng·h/mL, P < .05), lower dose-normalized peak concentrations (0.77 ± 0.51 vs 4.04 ± 3.18 ng/mL, P < .05), and larger weight-adjusted apparent oral volume of distribution (302 ± 112 vs 116 ± 45 L/kg, P < .05).",Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257615/),[l] / [h],20.1,104530,DB01275,Hydralazine
,31257615,dose-normalized area under the concentration-time curve (AUC,"During pregnancy, when compared with the SA group, the RA group had faster weight-adjusted hydralazine apparent oral clearance (70.0 ± 13.6 vs 20.1 ± 6.9 L/h, P < .05), lower dose-normalized area under the concentration-time curve (AUC; 1.5 ± 0.8 vs 5.9 ± 3.7 ng·h/mL, P < .05), lower dose-normalized peak concentrations (0.77 ± 0.51 vs 4.04 ± 3.18 ng/mL, P < .05), and larger weight-adjusted apparent oral volume of distribution (302 ± 112 vs 116 ± 45 L/kg, P < .05).",Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257615/),[h·ng] / [ml],1.5,104531,DB01275,Hydralazine
,31257615,dose-normalized area under the concentration-time curve (AUC,"During pregnancy, when compared with the SA group, the RA group had faster weight-adjusted hydralazine apparent oral clearance (70.0 ± 13.6 vs 20.1 ± 6.9 L/h, P < .05), lower dose-normalized area under the concentration-time curve (AUC; 1.5 ± 0.8 vs 5.9 ± 3.7 ng·h/mL, P < .05), lower dose-normalized peak concentrations (0.77 ± 0.51 vs 4.04 ± 3.18 ng/mL, P < .05), and larger weight-adjusted apparent oral volume of distribution (302 ± 112 vs 116 ± 45 L/kg, P < .05).",Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257615/),[h·ng] / [ml],5.9,104532,DB01275,Hydralazine
,31257615,dose-normalized peak concentrations,"During pregnancy, when compared with the SA group, the RA group had faster weight-adjusted hydralazine apparent oral clearance (70.0 ± 13.6 vs 20.1 ± 6.9 L/h, P < .05), lower dose-normalized area under the concentration-time curve (AUC; 1.5 ± 0.8 vs 5.9 ± 3.7 ng·h/mL, P < .05), lower dose-normalized peak concentrations (0.77 ± 0.51 vs 4.04 ± 3.18 ng/mL, P < .05), and larger weight-adjusted apparent oral volume of distribution (302 ± 112 vs 116 ± 45 L/kg, P < .05).",Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257615/),[ng] / [ml],0.77,104533,DB01275,Hydralazine
,31257615,dose-normalized peak concentrations,"During pregnancy, when compared with the SA group, the RA group had faster weight-adjusted hydralazine apparent oral clearance (70.0 ± 13.6 vs 20.1 ± 6.9 L/h, P < .05), lower dose-normalized area under the concentration-time curve (AUC; 1.5 ± 0.8 vs 5.9 ± 3.7 ng·h/mL, P < .05), lower dose-normalized peak concentrations (0.77 ± 0.51 vs 4.04 ± 3.18 ng/mL, P < .05), and larger weight-adjusted apparent oral volume of distribution (302 ± 112 vs 116 ± 45 L/kg, P < .05).",Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257615/),[ng] / [ml],4.04,104534,DB01275,Hydralazine
,31257615,weight-adjusted,"During pregnancy, when compared with the SA group, the RA group had faster weight-adjusted hydralazine apparent oral clearance (70.0 ± 13.6 vs 20.1 ± 6.9 L/h, P < .05), lower dose-normalized area under the concentration-time curve (AUC; 1.5 ± 0.8 vs 5.9 ± 3.7 ng·h/mL, P < .05), lower dose-normalized peak concentrations (0.77 ± 0.51 vs 4.04 ± 3.18 ng/mL, P < .05), and larger weight-adjusted apparent oral volume of distribution (302 ± 112 vs 116 ± 45 L/kg, P < .05).",Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257615/),[l] / [kg],302,104535,DB01275,Hydralazine
,31257615,apparent oral volume of distribution,"During pregnancy, when compared with the SA group, the RA group had faster weight-adjusted hydralazine apparent oral clearance (70.0 ± 13.6 vs 20.1 ± 6.9 L/h, P < .05), lower dose-normalized area under the concentration-time curve (AUC; 1.5 ± 0.8 vs 5.9 ± 3.7 ng·h/mL, P < .05), lower dose-normalized peak concentrations (0.77 ± 0.51 vs 4.04 ± 3.18 ng/mL, P < .05), and larger weight-adjusted apparent oral volume of distribution (302 ± 112 vs 116 ± 45 L/kg, P < .05).",Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257615/),[l] / [kg],302,104536,DB01275,Hydralazine
,31257615,apparent oral volume of distribution,"During pregnancy, when compared with the SA group, the RA group had faster weight-adjusted hydralazine apparent oral clearance (70.0 ± 13.6 vs 20.1 ± 6.9 L/h, P < .05), lower dose-normalized area under the concentration-time curve (AUC; 1.5 ± 0.8 vs 5.9 ± 3.7 ng·h/mL, P < .05), lower dose-normalized peak concentrations (0.77 ± 0.51 vs 4.04 ± 3.18 ng/mL, P < .05), and larger weight-adjusted apparent oral volume of distribution (302 ± 112 vs 116 ± 45 L/kg, P < .05).",Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257615/),[l] / [kg],116,104537,DB01275,Hydralazine
,31257615,AUC ratio,"Furthermore, the MTP/hydralazine AUC ratio was ∼10-fold higher in the RA group (78 ± 30 vs 8 ± 3, P < .05) than in the SA group.",Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257615/),,78,104538,DB01275,Hydralazine
,31257615,AUC ratio,"Furthermore, the MTP/hydralazine AUC ratio was ∼10-fold higher in the RA group (78 ± 30 vs 8 ± 3, P < .05) than in the SA group.",Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257615/),,8,104539,DB01275,Hydralazine
,6469433,terminal elimination half-life,Following acute administration the terminal elimination half-life of endralazine was approximately 2.5 h and the oral bioavailability was 75%.,Clinical pharmacological studies with the vasodilator endralazine in normotensive subjects and essential hypertensives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469433/),h,2.5,106644,DB01275,Hydralazine
,6469433,oral bioavailability,Following acute administration the terminal elimination half-life of endralazine was approximately 2.5 h and the oral bioavailability was 75%.,Clinical pharmacological studies with the vasodilator endralazine in normotensive subjects and essential hypertensives. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469433/),%,75,106645,DB01275,Hydralazine
,6469433,terminal elimination half-life,"During chronic dosing with endralazine the terminal elimination half-life significantly increased to a mean of 7.5 h, but there was no accumulation of drug.",Clinical pharmacological studies with the vasodilator endralazine in normotensive subjects and essential hypertensives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469433/),h,7.5,106646,DB01275,Hydralazine
,515498,plasma half life,"The mean plasma half life of the pyruvic acid hydrazone was 156 min and mean urinary clearance, 28 ml/min.","Pharmacokinetics of hydralazine, apparent hydralazine and hydralazine pyruvic acid hydrazone in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/515498/),min,156,107685,DB01275,Hydralazine
,515498,urinary clearance,"The mean plasma half life of the pyruvic acid hydrazone was 156 min and mean urinary clearance, 28 ml/min.","Pharmacokinetics of hydralazine, apparent hydralazine and hydralazine pyruvic acid hydrazone in humans. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/515498/),[ml] / [min],28,107686,DB01275,Hydralazine
,7102525,half-lives of the excretion,"The half-lives of the excretion of radioactivity were 3.0, 1.2, and less than 100 hours.",Pharmacokinetics of pindolol in humans and several animal species. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102525/),h,3.0,108999,DB01275,Hydralazine
,7102525,half-lives of the excretion,"The half-lives of the excretion of radioactivity were 3.0, 1.2, and less than 100 hours.",Pharmacokinetics of pindolol in humans and several animal species. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102525/),h,1.2,109000,DB01275,Hydralazine
,7102525,half-lives of the excretion,"The half-lives of the excretion of radioactivity were 3.0, 1.2, and less than 100 hours.",Pharmacokinetics of pindolol in humans and several animal species. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102525/),h,less,109001,DB01275,Hydralazine
,7102525,half-lives of the excretion,"The half-lives of the excretion of radioactivity were 3.0, 1.2, and less than 100 hours.",Pharmacokinetics of pindolol in humans and several animal species. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102525/),h,100,109002,DB01275,Hydralazine
,6148869,plasma elimination half-life,In nine patients the plasma elimination half-life of unchanged nadolol averaged 26 hours following a single 40 mg oral dose during the interdialytic period.,Nadolol in hypertensive patients maintained on long-term hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148869/),h,26,111216,DB01275,Hydralazine
,3432333,half lives,1 was distributed in rabbits and dogs in two phases with half lives of 0.25-0.4 min and 1.0-2.0 min.,[Pharmacokinetics of dihydralazine following intravenous administration in laboratory animals]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3432333/),min,0.25-0.4,112522,DB01275,Hydralazine
,3432333,half lives,1 was distributed in rabbits and dogs in two phases with half lives of 0.25-0.4 min and 1.0-2.0 min.,[Pharmacokinetics of dihydralazine following intravenous administration in laboratory animals]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3432333/),min,1.0-2.0,112523,DB01275,Hydralazine
,3432333,bile/serum,Dogs accumulated the drug in bile (bile/serum-ratios = 19-390).,[Pharmacokinetics of dihydralazine following intravenous administration in laboratory animals]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3432333/),,19-390,112524,DB01275,Hydralazine
,2100625,detection limit,The detection limit is 1 ng ml-1 and the relative standard deviation is less than 2.4.,Liquid chromatographic determination of hydralazine in human plasma with 2-hydroxy-1-naphthaldehyde pre-column derivatization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2100625/),[ng] / [ml],1,113025,DB01275,Hydralazine
,6653651,system bioavailability,E had high system bioavailability (73.5-99.1%) suggesting that it was almost completely absorbed without undergoing appreciable first-pass metabolism.,Endralazine - a new hydralazine-like antihypertensive with high systemic bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653651/),%,73.5-99.1,138329,DB01275,Hydralazine
less,6653651,systemic bioavailability,"This behavior contrasts with that of hydralazine where systemic bioavailability was less than 40%, and 2 to 3 times higher in slow acetylators than in fast acetylators.",Endralazine - a new hydralazine-like antihypertensive with high systemic bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653651/),%,40,138330,DB01275,Hydralazine
,6177931,potency ratio,"Both compounds caused a dose-dependent depressor response, with a potency ratio of HAH to H of approximately 0.2.",Hypotensive effect of the hydralazine--acetone hydrazone in conscious rabbits: evidence for its back-conversion to hydralazine in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6177931/),,0.2,162134,DB01275,Hydralazine
,8499134,plasma area under the curve,Co-administration of hydralazine decreases EO9 plasma clearance and increases plasma area under the curve values (0.053 to 0.115 micrograms h/ml).,Potentiation of EO9 anti-tumour activity by hydralazine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8499134/),[h·μg] / [ml],0.053 to 0.115,167912,DB01275,Hydralazine
,6840172,peak level (Cmax,"After fasting, the peak level (Cmax = 29.1 +/- 3.2 ng/ml; mean +/- SEM) was reached at 1.3 +/- 0.1 h (Tmax).","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ng] / [ml],29.1,178034,DB01275,Hydralazine
,6840172,Tmax,"After fasting, the peak level (Cmax = 29.1 +/- 3.2 ng/ml; mean +/- SEM) was reached at 1.3 +/- 0.1 h (Tmax).","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),h,1.3,178035,DB01275,Hydralazine
,6840172,total area under the serum concentration-time curve (AUC0-infinity),"The total area under the serum concentration-time curve (AUC0-infinity) was 154.4 +/- 33.8 ng x h/ml, total clearance (Cltot) 751.5 +/- 90.6 ml/min, renal clearance (Clren) 97.2 +/- 10.1 ml/min, elimination half-life (t1/2) 2.9 +/- 0.3 h and 24-h recovery in urine (X0u-24) 11.1 +/- 1.4% of the dose.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[h·ng] / [ml],154.4,178036,DB01275,Hydralazine
,6840172,total clearance (Cltot),"The total area under the serum concentration-time curve (AUC0-infinity) was 154.4 +/- 33.8 ng x h/ml, total clearance (Cltot) 751.5 +/- 90.6 ml/min, renal clearance (Clren) 97.2 +/- 10.1 ml/min, elimination half-life (t1/2) 2.9 +/- 0.3 h and 24-h recovery in urine (X0u-24) 11.1 +/- 1.4% of the dose.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ml] / [min],751.5,178037,DB01275,Hydralazine
,6840172,renal clearance (Clren),"The total area under the serum concentration-time curve (AUC0-infinity) was 154.4 +/- 33.8 ng x h/ml, total clearance (Cltot) 751.5 +/- 90.6 ml/min, renal clearance (Clren) 97.2 +/- 10.1 ml/min, elimination half-life (t1/2) 2.9 +/- 0.3 h and 24-h recovery in urine (X0u-24) 11.1 +/- 1.4% of the dose.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ml] / [min],97.2,178038,DB01275,Hydralazine
,6840172,elimination half-life (t1/2),"The total area under the serum concentration-time curve (AUC0-infinity) was 154.4 +/- 33.8 ng x h/ml, total clearance (Cltot) 751.5 +/- 90.6 ml/min, renal clearance (Clren) 97.2 +/- 10.1 ml/min, elimination half-life (t1/2) 2.9 +/- 0.3 h and 24-h recovery in urine (X0u-24) 11.1 +/- 1.4% of the dose.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),h,2.9,178039,DB01275,Hydralazine
,6840172,Cmax,"Dihydralazine enhanced Cmax (38.2 +/- 4.6 ng/ml) only when compared to phenobarbitone treatment, and did not affect any other parameters.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ng] / [ml],38.2,178040,DB01275,Hydralazine
,6840172,Cmax,"Phenobarbitone pretreatment somewhat lowered Cmax (25.5 +/- 3.9 ng/ml), AUC0-infinity (117.5 +/- 22.1; p less than 0.05 vs food) and X0u-24 (8.7 +/- 1.2%), evidently by increasing Cltot (957.5 +/- 116.9 ml/min; p less than 0.05 vs food), but it did not affect Clren.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ng] / [ml],25.5,178041,DB01275,Hydralazine
,6840172,AUC0-infinity,"Phenobarbitone pretreatment somewhat lowered Cmax (25.5 +/- 3.9 ng/ml), AUC0-infinity (117.5 +/- 22.1; p less than 0.05 vs food) and X0u-24 (8.7 +/- 1.2%), evidently by increasing Cltot (957.5 +/- 116.9 ml/min; p less than 0.05 vs food), but it did not affect Clren.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),,117.5,178042,DB01275,Hydralazine
,6840172,Cltot,"Phenobarbitone pretreatment somewhat lowered Cmax (25.5 +/- 3.9 ng/ml), AUC0-infinity (117.5 +/- 22.1; p less than 0.05 vs food) and X0u-24 (8.7 +/- 1.2%), evidently by increasing Cltot (957.5 +/- 116.9 ml/min; p less than 0.05 vs food), but it did not affect Clren.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ml] / [min],957.5,178043,DB01275,Hydralazine
,552862,peak of mean plasma concentrations,"After single oral doses of 20 mg of a suspension of dihydralazine sulphate to human subjects, the peak of mean plasma concentrations of dihydralazine of 47.0 ng ml-1 +/- 11.0 standard deviation (S.D.) (n = 7) was reached at 1 h.",Plasma concentrations and pharmacokinetics of dihydralazine after single oral doses to human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/552862/),[ng] / [ml],47.0,189425,DB01275,Hydralazine
,552862,apparent half-lives,Mean concentrations declined biphasically with apparent half-lives of 0.57 and 4.96 h respectively.,Plasma concentrations and pharmacokinetics of dihydralazine after single oral doses to human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/552862/),h,0.57,189426,DB01275,Hydralazine
,552862,apparent half-lives,Mean concentrations declined biphasically with apparent half-lives of 0.57 and 4.96 h respectively.,Plasma concentrations and pharmacokinetics of dihydralazine after single oral doses to human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/552862/),h,4.96,189427,DB01275,Hydralazine
,552862,clearances,Mean clearances appeared to be slightly more rapid in fast acetylators (1.63 l min-1 +/- 0.32 S.D.) when compared to slow acetylators (1.31 l min-1 +/- 0.31 S.D.) but this difference and differences in plasma concentrations and in areas under the plasma drug concentration-time curves were not significant (p > 0.1).,Plasma concentrations and pharmacokinetics of dihydralazine after single oral doses to human subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/552862/),[l] / [min],1.63,189428,DB01275,Hydralazine
,552862,clearances,Mean clearances appeared to be slightly more rapid in fast acetylators (1.63 l min-1 +/- 0.32 S.D.) when compared to slow acetylators (1.31 l min-1 +/- 0.31 S.D.) but this difference and differences in plasma concentrations and in areas under the plasma drug concentration-time curves were not significant (p > 0.1).,Plasma concentrations and pharmacokinetics of dihydralazine after single oral doses to human subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/552862/),[l] / [min],1.31,189429,DB01275,Hydralazine
,7438695,bioavailability,"Hydralazine bioavailability in the fast acetylator group (9.5% single dose, 6.6% repeated doses) and in the slow acetylator group (31.3% single dose, 39.3% repeated doses) was phenotype dependent.",Hydralazine kinetics after single and repeated oral doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438695/),%,9.5,190285,DB01275,Hydralazine
,7438695,bioavailability,"Hydralazine bioavailability in the fast acetylator group (9.5% single dose, 6.6% repeated doses) and in the slow acetylator group (31.3% single dose, 39.3% repeated doses) was phenotype dependent.",Hydralazine kinetics after single and repeated oral doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438695/),%,6.6,190286,DB01275,Hydralazine
,7438695,bioavailability,"Hydralazine bioavailability in the fast acetylator group (9.5% single dose, 6.6% repeated doses) and in the slow acetylator group (31.3% single dose, 39.3% repeated doses) was phenotype dependent.",Hydralazine kinetics after single and repeated oral doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438695/),%,31.3,190287,DB01275,Hydralazine
,7438695,bioavailability,"Hydralazine bioavailability in the fast acetylator group (9.5% single dose, 6.6% repeated doses) and in the slow acetylator group (31.3% single dose, 39.3% repeated doses) was phenotype dependent.",Hydralazine kinetics after single and repeated oral doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438695/),%,39.3,190288,DB01275,Hydralazine
,7438695,Peak plasma levels,Peak plasma levels were lower than those reported with nonspecific assays: 0.32 microM for the single dose and 0.14 microM for repeated doses in the fast acetylator group and 1.03 microM for the single dose and 0.96 microM repeated doses in the slow acetylator group.,Hydralazine kinetics after single and repeated oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438695/),μM,0.32,190289,DB01275,Hydralazine
,7438695,Peak plasma levels,Peak plasma levels were lower than those reported with nonspecific assays: 0.32 microM for the single dose and 0.14 microM for repeated doses in the fast acetylator group and 1.03 microM for the single dose and 0.96 microM repeated doses in the slow acetylator group.,Hydralazine kinetics after single and repeated oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438695/),μM,0.14,190290,DB01275,Hydralazine
,7438695,Peak plasma levels,Peak plasma levels were lower than those reported with nonspecific assays: 0.32 microM for the single dose and 0.14 microM for repeated doses in the fast acetylator group and 1.03 microM for the single dose and 0.96 microM repeated doses in the slow acetylator group.,Hydralazine kinetics after single and repeated oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438695/),μM,1.03,190291,DB01275,Hydralazine
,7438695,Peak plasma levels,Peak plasma levels were lower than those reported with nonspecific assays: 0.32 microM for the single dose and 0.14 microM for repeated doses in the fast acetylator group and 1.03 microM for the single dose and 0.96 microM repeated doses in the slow acetylator group.,Hydralazine kinetics after single and repeated oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438695/),μM,0.96,190292,DB01275,Hydralazine
,7438695,Elimination half-lifes,"Elimination half-lifes were phenotype independent, ranging from 4 to 6 hr.",Hydralazine kinetics after single and repeated oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438695/),h,4 to 6,190293,DB01275,Hydralazine
,3944813,time,"The mean time between 1st and 2nd dose was 5.7 hours, 2nd and 3rd 6.1 hours and between 3rd and 1st of the next day 12.2 hours.",Three times daily or 8-hourly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3944813/),h,5.7,191009,DB01275,Hydralazine
,3944813,time,"The mean time between 1st and 2nd dose was 5.7 hours, 2nd and 3rd 6.1 hours and between 3rd and 1st of the next day 12.2 hours.",Three times daily or 8-hourly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3944813/),h,6.1,191010,DB01275,Hydralazine
,3944813,time,"The mean time between 1st and 2nd dose was 5.7 hours, 2nd and 3rd 6.1 hours and between 3rd and 1st of the next day 12.2 hours.",Three times daily or 8-hourly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3944813/),h,12.2,191011,DB01275,Hydralazine
,1558786,plasma clearance,Inulin plasma clearance was decreased from 0.258 +/- 0.046 ml min-1 to 0.096 +/- 0.017 ml min-1 (a factor of 2.69) after administration of hydralazine.,Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1558786/),[ml] / [min],0.258,200681,DB01275,Hydralazine
,1558786,plasma clearance,Inulin plasma clearance was decreased from 0.258 +/- 0.046 ml min-1 to 0.096 +/- 0.017 ml min-1 (a factor of 2.69) after administration of hydralazine.,Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1558786/),[ml] / [min],0.096,200682,DB01275,Hydralazine
,4053489,F,The F value in six subjects with CLsmz greater than 100 ml/min was 9.9% +/- 6.0% (means +/- SD) and was lower than the value of 26.2% +/- 13.0% (P less than 0.05) in the four patients with CLsmz less than 60 ml/min.,Determinants of systemic availability of oral hydralazine in heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4053489/),%,9.9,203547,DB01275,Hydralazine
,4053489,F,The F value in six subjects with CLsmz greater than 100 ml/min was 9.9% +/- 6.0% (means +/- SD) and was lower than the value of 26.2% +/- 13.0% (P less than 0.05) in the four patients with CLsmz less than 60 ml/min.,Determinants of systemic availability of oral hydralazine in heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4053489/),%,26.2,203548,DB01275,Hydralazine
,4053489,clearance,"The clearance of the single intravenous dose of hydralazine averaged 29.5 +/- 8.0 ml/min/kg, which is not different than that reported in populations without heart failure.",Determinants of systemic availability of oral hydralazine in heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4053489/),[ml] / [kg·min],29.5,203549,DB01275,Hydralazine
,4053489,AUC,"After oral dosage titration to induce maximum hemodynamic changes, the dose-normalized hydralazine AUC rose from 53.5 +/- 50.5 to 247.2 +/- 213.4 min/L X 10(3).",Determinants of systemic availability of oral hydralazine in heart failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4053489/),[l·min] / [10(3],53.5,203550,DB01275,Hydralazine
,4053489,AUC,"After oral dosage titration to induce maximum hemodynamic changes, the dose-normalized hydralazine AUC rose from 53.5 +/- 50.5 to 247.2 +/- 213.4 min/L X 10(3).",Determinants of systemic availability of oral hydralazine in heart failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4053489/),[l·min] / [10(3],247.2,203551,DB01275,Hydralazine
,483859,Peak plasma levels,2. Peak plasma levels of 14C were 3.6 microgram equiv.,"Metabolism of budralazine, a new antihypertensive agent, III. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/483859/),equiv·μg,3.6,209824,DB01275,Hydralazine
,24702251,AUC0-48 h,"The AUC0-48 h and Cmax of hydralazine were almost identical (1410 ± 560 vs. 1446 ± 509 ng h/mL and 93·4 ± 16·7 vs. 112·5 ± 42·1 ng/mL) in both groups with NAT2 genotype-adjusted doses, whereas the multidose parameters of valproate were not significantly affected neither by the selection of the NAT2 genotype (AUC0-48 h 2064 ± 455 vs.",Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24702251/),[h·ng] / [ml],1410,210935,DB01275,Hydralazine
,24702251,AUC0-48 h,"The AUC0-48 h and Cmax of hydralazine were almost identical (1410 ± 560 vs. 1446 ± 509 ng h/mL and 93·4 ± 16·7 vs. 112·5 ± 42·1 ng/mL) in both groups with NAT2 genotype-adjusted doses, whereas the multidose parameters of valproate were not significantly affected neither by the selection of the NAT2 genotype (AUC0-48 h 2064 ± 455 vs.",Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24702251/),[h·ng] / [ml],1446,210936,DB01275,Hydralazine
,24702251,Cmax,"The AUC0-48 h and Cmax of hydralazine were almost identical (1410 ± 560 vs. 1446 ± 509 ng h/mL and 93·4 ± 16·7 vs. 112·5 ± 42·1 ng/mL) in both groups with NAT2 genotype-adjusted doses, whereas the multidose parameters of valproate were not significantly affected neither by the selection of the NAT2 genotype (AUC0-48 h 2064 ± 455 vs.",Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24702251/),[h·ng] / [ml],1446,210937,DB01275,Hydralazine
,24702251,Cmax,"The AUC0-48 h and Cmax of hydralazine were almost identical (1410 ± 560 vs. 1446 ± 509 ng h/mL and 93·4 ± 16·7 vs. 112·5 ± 42·1 ng/mL) in both groups with NAT2 genotype-adjusted doses, whereas the multidose parameters of valproate were not significantly affected neither by the selection of the NAT2 genotype (AUC0-48 h 2064 ± 455 vs.",Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24702251/),[ng] / [ml],93·4,210938,DB01275,Hydralazine
,24702251,Cmax,"The AUC0-48 h and Cmax of hydralazine were almost identical (1410 ± 560 vs. 1446 ± 509 ng h/mL and 93·4 ± 16·7 vs. 112·5 ± 42·1 ng/mL) in both groups with NAT2 genotype-adjusted doses, whereas the multidose parameters of valproate were not significantly affected neither by the selection of the NAT2 genotype (AUC0-48 h 2064 ± 455 vs.",Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24702251/),[ng] / [ml],112·5,210939,DB01275,Hydralazine
,24702251,AUC0-48 h,"The AUC0-48 h and Cmax of hydralazine were almost identical (1410 ± 560 vs. 1446 ± 509 ng h/mL and 93·4 ± 16·7 vs. 112·5 ± 42·1 ng/mL) in both groups with NAT2 genotype-adjusted doses, whereas the multidose parameters of valproate were not significantly affected neither by the selection of the NAT2 genotype (AUC0-48 h 2064 ± 455 vs.",Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24702251/),,2064,210940,DB01275,Hydralazine
,24702251,Cmax,1896 ± 185 μg h/mL; Cmax 96·4 ± 21·1 vs.,Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24702251/),,96·4,210941,DB01275,Hydralazine
,4087193,areas under the plasma concentration-time curves,"After oral administration of 25 mg of 1 to 2 healthy volunteers, the mean areas under the plasma concentration-time curves were respectively 43.7 and 590 ng X h/mL for unchanged and apparent 1.",Liquid chromatographic determination of dihydralazine and hydralazine in human plasma and its application to pharmacokinetic studies of dihydralazine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087193/),[h·ng] / [ml],43.7,216535,DB01275,Hydralazine
,4087193,areas under the plasma concentration-time curves,"After oral administration of 25 mg of 1 to 2 healthy volunteers, the mean areas under the plasma concentration-time curves were respectively 43.7 and 590 ng X h/mL for unchanged and apparent 1.",Liquid chromatographic determination of dihydralazine and hydralazine in human plasma and its application to pharmacokinetic studies of dihydralazine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087193/),[h·ng] / [ml],590,216536,DB01275,Hydralazine
,4087193,elimination half-lives,The corresponding mean elimination half-lives were 1.03 and 3.9 h.,Liquid chromatographic determination of dihydralazine and hydralazine in human plasma and its application to pharmacokinetic studies of dihydralazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087193/),h,1.03,216537,DB01275,Hydralazine
,4087193,elimination half-lives,The corresponding mean elimination half-lives were 1.03 and 3.9 h.,Liquid chromatographic determination of dihydralazine and hydralazine in human plasma and its application to pharmacokinetic studies of dihydralazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087193/),h,3.9,216538,DB01275,Hydralazine
,6599716,terminal elimination half-life,Following acute administration the terminal elimination half-life of endralazine was approximately 2.5 h and the oral bioavailability was 75%.,Pharmacodynamic and pharmacokinetic studies with the vasodilator endralazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6599716/),h,2.5,228916,DB01275,Hydralazine
,6599716,oral bioavailability,Following acute administration the terminal elimination half-life of endralazine was approximately 2.5 h and the oral bioavailability was 75%.,Pharmacodynamic and pharmacokinetic studies with the vasodilator endralazine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6599716/),%,75,228917,DB01275,Hydralazine
,6599716,elimination half-life,During chronic treatment the elimination half-life significantly increased to about 7.5 h.,Pharmacodynamic and pharmacokinetic studies with the vasodilator endralazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6599716/),h,7.5,228918,DB01275,Hydralazine
,7438689,"Total plasma clearance, CLT","Total plasma clearance, CLT[72.9 +/- 4.9 (SEM) ml . min-1 . kg-1], apparent volume of distribution, Vd area (5.83 +/- 0.30 1 . kg-1), steady-state volume of distribution, Vd ss (1.83 +/- 0.17 . kg-1), and terminal half-life, t1/2 (53.7 min, harmonic mean) were independent of acetylator phenotype.",Hydralazine kinetics in hypertensive patients after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438689/),[ml] / [kg·min],72.9,232889,DB01275,Hydralazine
,7438689,"apparent volume of distribution, Vd area","Total plasma clearance, CLT[72.9 +/- 4.9 (SEM) ml . min-1 . kg-1], apparent volume of distribution, Vd area (5.83 +/- 0.30 1 . kg-1), steady-state volume of distribution, Vd ss (1.83 +/- 0.17 . kg-1), and terminal half-life, t1/2 (53.7 min, harmonic mean) were independent of acetylator phenotype.",Hydralazine kinetics in hypertensive patients after intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438689/),[1] / [kg],5.83,232890,DB01275,Hydralazine
,7438689,"steady-state volume of distribution, Vd ss","Total plasma clearance, CLT[72.9 +/- 4.9 (SEM) ml . min-1 . kg-1], apparent volume of distribution, Vd area (5.83 +/- 0.30 1 . kg-1), steady-state volume of distribution, Vd ss (1.83 +/- 0.17 . kg-1), and terminal half-life, t1/2 (53.7 min, harmonic mean) were independent of acetylator phenotype.",Hydralazine kinetics in hypertensive patients after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438689/),1/[kg],1.83,232891,DB01275,Hydralazine
,7438689,"terminal half-life, t1/2","Total plasma clearance, CLT[72.9 +/- 4.9 (SEM) ml . min-1 . kg-1], apparent volume of distribution, Vd area (5.83 +/- 0.30 1 . kg-1), steady-state volume of distribution, Vd ss (1.83 +/- 0.17 . kg-1), and terminal half-life, t1/2 (53.7 min, harmonic mean) were independent of acetylator phenotype.",Hydralazine kinetics in hypertensive patients after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438689/),min,53.7,232892,DB01275,Hydralazine
,7438689,t1/2,Peak HPH concentrations occurred 10 to 60 min after dose; mean HPH t1/2 was 239 min.,Hydralazine kinetics in hypertensive patients after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438689/),min,239,232893,DB01275,Hydralazine
,7438689,t1/2,"""Apparent"" hydralazine concentrations were usually highest in the 2-min plasma sample and declined with a mean t1/2 of 296 min.",Hydralazine kinetics in hypertensive patients after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438689/),min,296,232894,DB01275,Hydralazine
,7273593,Oral bioavailability,Oral bioavailability of 1- and total propranolol averaged 40.7 +/- 8.5% and 42.4 +/- 12.9%.,No stereoselective first-pass hepatic extraction of propranolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273593/),%,40.7,241870,DB01275,Hydralazine
,7273593,Oral bioavailability,Oral bioavailability of 1- and total propranolol averaged 40.7 +/- 8.5% and 42.4 +/- 12.9%.,No stereoselective first-pass hepatic extraction of propranolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273593/),%,42.4,241871,DB01275,Hydralazine
,18716369,vascular peroxynitrite,The vascular peroxynitrite concentration was 1.6 pmol/mg protein in the control group and significantly less than those in the P- and V-monotherapy-groups.,Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18716369/),[pM] / [mg],1.6,254078,DB01275,Hydralazine
,18716369,concentration,The vascular peroxynitrite concentration was 1.6 pmol/mg protein in the control group and significantly less than those in the P- and V-monotherapy-groups.,Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18716369/),[pM] / [mg],1.6,254079,DB01275,Hydralazine
,1001354,0-24 h,"The 0-24 h excretion of the drug in urine was rapid: 11.4-14.1% of the dose after intravenous administration, and 2.0-3.6% after an oral dose.",Studies on hydralazine. Bioavailability of hydralazine in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1001354/),%,11.4-14.1,261995,DB01275,Hydralazine
,1001354,0-24 h,"The 0-24 h excretion of the drug in urine was rapid: 11.4-14.1% of the dose after intravenous administration, and 2.0-3.6% after an oral dose.",Studies on hydralazine. Bioavailability of hydralazine in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1001354/),%,2.0-3.6,261996,DB01275,Hydralazine
,1001354,excretion,"The 0-24 h excretion of the drug in urine was rapid: 11.4-14.1% of the dose after intravenous administration, and 2.0-3.6% after an oral dose.",Studies on hydralazine. Bioavailability of hydralazine in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1001354/),%,11.4-14.1,261997,DB01275,Hydralazine
,1001354,excretion,"The 0-24 h excretion of the drug in urine was rapid: 11.4-14.1% of the dose after intravenous administration, and 2.0-3.6% after an oral dose.",Studies on hydralazine. Bioavailability of hydralazine in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1001354/),%,2.0-3.6,261998,DB01275,Hydralazine
